'Top drawer IP set.'
Legal 500 2010
'An incredibly good set for IP matters'.
Legal 500 2010
'A veritable powerhouse of IP expertise'
Chambers and Partners 2011
'outstanding IP chambers'
Legal 500 2008
'Practical and helpful clerks" provide a "smooth and personable service.'
Chambers and Partners 2011
'clerking team that exhibits 'perfect communication''
Legal 500 2008
'excellence on IT matters'
Legal 500 (Information Technology) 2010
'A number of great IT and telecoms barristers.'
Legal 500 2010
'8 New Square successfully parlays its renowned IP expertise into success in the IT sector.'
Chambers & Partners (Information Technology) 2009
Life Sciences
Members of
Pharmaceuticals
Disputes about pharmaceutical patents have contributed a significant proportion of the litigation handled by members of chambers over recent years. By way of example, members of 8 New Square were involved in the Generics v Lundbeck (escitalopram) litigation which reached the House of Lords and in the following cases which have reached the Court of Appeal since 2005: Dr Reddy’s v Eli Lilly (olanzapine), Actavis v Novartis (CR fluvastatin), Actavis v Merck (finasteride), Generics v Daiichi (levofloxacin), Napp v ratiopharm (CR oxycodone), Leo v Sandoz (calcipotriol), Servier v Apotex( perindopril), Novartis v Ivax (cyclosporine microemulsion), GSK v Genentech (EGFR) and Ranbaxy v Warner-Lambert (atorvastatin). Members of chambers also appear in the EPO, including before the Enlarged Board of Appeal: G2/08 Abbott.
Disputes about SPCs are becoming increasingly common and members of chambers have considerable experience in this area, appearing both in the UK courts and in the Court of Justice – cases include Merck, Wellcome, BASF, Yissum, Takeda, Gilead, Astellas, Georgetown Univ. and Daiichi Sankyo.
Members of
Biotechnology
Members of chambers have been involved in nearly all the significant biotechnology patent litigation in the
More recently, members of chambers have acted in Yeda v Rhône-Poulenc Rorer (the entitlement dispute which reached the House of Lords), Eli Lilly v HGS (the leading UK case on industrial application of biotech inventions, now under appeal to the Supreme Court), Monsanto v Cargill (part of trans-national litigation on imported GM soymeal) and Intervet v Merial (porcine circovirus).
Members of chambers have also acted in biotech cases before the EPO, including disputes as to whether inventions were unpatentable because they related to plant or animal varieties or because they were contrary to morality: see T356/93 Plant Genetic Systems, T315/03 Harvard Univ. (oncomouse) & G2/06 Wisconsin (stem cells).
Medical devices
Members of 8 New Square have been involved in numerous disputes about patents for medical devices, including coronary stents and other devices for treatment of the cardiovascular system (Conor v Angiotech, Abbott v Evysio, Occlutech v AGA, Cook v Edwards, Abbott v Medinol), contact lenses (Novartis v J&J) and wound therapy devices (Wake Forest v Smith & Nephew, Mölnlycke v Wake Forest, KCI v Smith & Nephew).
Contractual disputes and arbitrations
Members of chambers are regularly involved in disputes concerning licensing of intellectual property rights. In the life sciences area these have included CAT v Abbott and Celltech v MedImmune (both concerning antibody engineering technology). Members of chambers have also been involved in significant arbitrations in the pharmaceutical and biotechnology field.
Regulatory disputes
Members of
Plant breeders' rights
Litigation in this field is relatively rare, but when it does occur chambers tends to be involved: see Germinal v Fell (grass seed) and, in a related field, Munoz v Frumar (grape varieties).

